Teva Pharmaceutical (NYSE: TEVA) EVP exercises options and sells stock

Rhea-AI Filing Summary

Teva Pharmaceutical Industries executive Mark Sabag, Executive Vice President, International Markets Commercial, reported an option exercise and related share sales. On 12/09/2025, he exercised stock options to buy 118,724 Ordinary Shares at an exercise price of $18.61 per share, increasing his directly held shares.

That same day, he sold 118,724 Ordinary Shares at a weighted average price of $28.748 per share and an additional 98,168 Ordinary Shares at a weighted average price of $28.7026 per share, both through multiple transactions within narrow price ranges. After these transactions, he directly owned 52,828 Ordinary Shares and held no remaining stock options from this grant. Each Ordinary Share may be represented by one American Depositary Share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sabag Mark

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See "Remarks"

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	12/09/2025		M		118,724	A	$18.61	269,720	D
Ordinary Shares(1)	12/09/2025		S		118,724	D	$28.748(2)	150,996	D
Ordinary Shares(1)	12/09/2025		S		98,168	D	$28.7026(3)	52,828	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$18.61	12/09/2025		M			118,724	(4)	02/09/2028	Ordinary Shares(1)	118,724	$0	0	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.705 to $28.845, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.675 to $28.745, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

4. Stock options were granted on February 9, 2018, with 39,574 vested on each of February 9, 2020, February 9, 2021 and February 9, 2022.

Remarks:

Executive Vice President, International Markets Commercial

	/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Teva (TEVA) executive Mark Sabag report?

Mark Sabag, Executive Vice President, International Markets Commercial at Teva Pharmaceutical Industries, reported exercising stock options for 118,724 Ordinary Shares and selling shares on 12/09/2025.

How many Teva (TEVA) shares did Mark Sabag acquire through option exercise?

He exercised stock options described as stock options (right to buy) for 118,724 Ordinary Shares at an exercise price of $18.61 per share on 12/09/2025.

At what prices did Teva (TEVA) executive Mark Sabag sell shares?

He sold 118,724 Ordinary Shares at a weighted average price of $28.748 per share and 98,168 Ordinary Shares at a weighted average price of $28.7026 per share, both on 12/09/2025.

How many Teva (TEVA) shares does Mark Sabag own after these transactions?

After the reported transactions, Mark Sabag directly owned 52,828 Ordinary Shares of Teva Pharmaceutical Industries.

What happened to Mark Sabag's Teva (TEVA) stock options in this filing?

The reported stock options (right to buy) with an exercise price of $18.61, originally granted on February 9, 2018, were exercised for 118,724 Ordinary Shares, and the remaining number of these options reported as beneficially owned became 0.

How are Teva (TEVA) Ordinary Shares represented in U.S. markets?

The filing notes that Ordinary Shares may be represented by American Depositary Shares, and that each American Depositary Share currently represents one Ordinary Share.